Le Lézard
Classified in: Health, Science and technology
Subject: Funding

Arima Genomics Completes Series A Financing


Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund.

"Agilent invests in industry partners to advance the development of new technologies that will accelerate the pace of scientific discoveries," said Tad Weems, Managing Director of Agilent's Early Stage Partnership Program. "Arima has the potential to unlock novel genomic applications by leading the community's transition from focusing on sequence alone toward sequence and structure."

The proceeds from this financing will go toward expanding Arima's commercial efforts, driving the development of new applications to the existing Arima HiC platform including adding structural analysis capabilities to conventional chromatin immunoprecipitation via HiChIP, and building new products including smooth-coverage HiC for applications in gap-less de novo assemblies and population sequencing. The funding will also support scaling of Arima's operations and enhancing customer service and support experience.

"Since the initial product launch in 2018, Arima has shown remarkable success in achieving customer confidence as demonstrated by rapid customer and revenue growth," said Siddarth Selvaraj, CEO and Co-founder of Arima Genomics, Inc. "We are excited to invite our investors to Arima's fascinating journey and thrilled to partner with them to drive the next phase of growth."

About Arima Genomics

Arima Genomics, Inc. is a biotechnology company that aims to accelerate the understanding of genome sequence and structure. To learn more, please visit www.arimagenomics.com.


These press releases may also interest you

at 01:00
PrecisionLife has confirmed it is extending its relationships with some of the largest COVID-19 collaborative research projects and is now offering free use of its unique analytics platform and support from its data and biomedical science teams to...

at 01:00
UK biotech Imophoron has produced multiple COVID-19 vaccine candidates, based on its novel vaccine platform (named the ADDomer©), within weeks of the virus sequence being made available....

at 01:00
We're all affected by the current COVID-19 crisis and we understand that preclinical and clinical research may be slowing down. InstantGMP, Inc. wants to help by awarding COVID-19 Stimulus Grants that can help biotech companies keep up with their...

at 00:00
COMPLIANCY GROUP in its ongoing efforts to educate HIPAA covered entities, business associates, and managed service providers, has developed several resources to provide guidance on working from home. With the COVID-19 outbreak, most businesses have...

at 00:00
FDA's Regulation of Digital Health Wearables & Sensors An FDAnews Webinar Tuesday, April 21, 2020 ? 1:30-3:00 p.m. EDT https://www.fdanews.com/wearablesandsensors The digital health wearable and sensors market is rapidly growing. What is one's...

6 avr 2020
Emerald Health Therapeutics, Inc. ("Emerald") announces that it intends to amend the terms of certain common share purchase warrants originally issued on September 9, 2019 (the "Warrants"). An aggregate of 12,500,000 Warrants were initially issued...



News published on 24 february 2020 at 08:10 and distributed by: